NASDAQ:PTPI Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis $0.03 +0.00 (+2.31%) As of 09/17/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Petros Pharmaceuticals Stock (NASDAQ:PTPI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Petros Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0352-Week Range$0.02▼$16.25Volume297,186 shsAverage Volume4.53 million shsMarket Capitalization$828.86 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. Read More Petros Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScorePTPI MarketRank™: Petros Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Petros Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Petros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Petros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPetros Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.72% of the float of Petros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPetros Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPetros Pharmaceuticals does not currently pay a dividend.Dividend GrowthPetros Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.72% of the float of Petros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPetros Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for PTPI on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Petros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.23% of the stock of Petros Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 12.34% of the stock of Petros Pharmaceuticals is held by institutions.Read more about Petros Pharmaceuticals' insider trading history. Receive PTPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTPI Stock News HeadlinesPetros Pharmaceuticals Inc (PTPI) - Investing.comSeptember 6, 2025 | investing.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company ...June 26, 2025 | finanznachrichten.deWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained to stay alive when systems collapse. In Operation Gold Rush, Jason Hanson reveals how gold and silver saved his life—and how they could protect yours in the next crisis. You’ll learn how to hide gold like a covert operative, secure your 401(k) in physical assets, and prepare for grid failures, economic collapse, or worse.September 18 at 2:00 AM | Advantage Gold (Ad)Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | MorningstarJune 26, 2025 | morningstar.comMPetros Pharmaceuticals to deconsolidate subsidiary to improve financesJune 26, 2025 | investing.comPetros Pharmaceuticals, Inc. (PTPI) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPetros Pharmaceuticals Inc News (PTPI) - Investing.comJune 26, 2025 | investing.comPetros Pharmaceuticals to appeal Nasdaq delisting decisionMay 23, 2025 | uk.investing.comSee More Headlines PTPI Stock Analysis - Frequently Asked Questions How have PTPI shares performed this year? Petros Pharmaceuticals' stock was trading at $9.8475 at the start of the year. Since then, PTPI stock has decreased by 99.7% and is now trading at $0.0266. How were Petros Pharmaceuticals' earnings last quarter? Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) released its quarterly earnings results on Thursday, May, 15th. The company reported ($8.46) earnings per share (EPS) for the quarter. When did Petros Pharmaceuticals' stock split? Petros Pharmaceuticals shares reverse split on the morning of Thursday, May 1st 2025.The 1-25 reverse split was announced on Tuesday, April 29th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Petros Pharmaceuticals? Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Petros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/15/2025Today9/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTPI CIK1815903 Webwww.petrospharma.com Phone973-242-0005FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($52.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.16 million Net MarginsN/A Pretax Margin-117.50% Return on Equity-78.22% Return on Assets-23.50% Debt Debt-to-Equity Ratio1.58 Current Ratio0.85 Quick Ratio0.74 Sales & Book Value Annual Sales$5.11 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.01Miscellaneous Outstanding Shares31,160,000Free Float9,932,000Market Cap$828.86 thousand OptionableNot Optionable Beta1.59 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:PTPI) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTPI Stock Alerts